Biogenerics: Turning visions into reality

The use of recombinant biotechnology to manufacture therapeutic drugs is based on a relatively long history. In 1983, recombinant human insulin became the first biotech therapeutic agent to be approved by the US Food and Drug Administration. Other products were launched on the market in the years that followed. Experts predict that the number of approved biotech-based products will soon exceed the number of approved chemical-based products.

BioGeneriX AG

The ratiopharm group recognized the importance of biogenerics early on and has been active in this field since the late 1990s. Establishing the BioGeneriX company in 2000 was the next logical step in the group's business segment strategy. As a wholly-owned ratiopharm subsidiary, BioGeneriX focuses on the biopharmaceutical and clinical development of suitable biogeneric substances.

As a strategic start-up, BioGeneriX AG aims to develop bioengineered drugs for known targets. Backed by a number of functional partnerships and strategic alliances, the unique character of BioGeneriX was shaped in a specific entrepreneurial setting within the existing ratiopharm structure.

BioGeneriX benefits significantly from its first mover advantage and the combined strength of its internal and external resources. All stakeholders – employees as well as business affiliates – share this vision of success.